Zai Lab Limited

NASDAQ:ZLAB

Biotechnology

Healthcare
$22.11 +3.42%

+$0.61 today

Market cap
$2.49B
Beta
0.78
P/E (TTM)
-11.4
EPS (TTM)
-$0.16
52W Low $15.96High $41.20

Volume 1.04M

Average 0.87M

ZLAB Income Before Tax

Profit after all operating and non-operating items but before income tax.

Zai Lab LimitedNASDAQ: ZLAB

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax remains negative

Q2 FY2026 income before tax was -$51.85M, compared with -$40.73M a year earlier. Trailing-twelve-month income before tax was -$190.72M.

Context

  • Income before tax amounted to 38.8% of revenue in FY2025, down 25.7 pp from a year earlier.
  • Income before tax grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$51.85M or moves back toward the trailing-twelve-month quarterly average of -$47.68M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$51.85M-4.6% QoQ
Last fiscal yearDec 2025
-$178.46M+30.6% YoY
LTMJun 2026
-$190.72M+10.3% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.3%——
1 year+30.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(178.46M) USD
Year-over-year change
+30.6%

Income Before Tax vs competitors

How ZLAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +10.3% is the 2nd highest of 3, against a peer median of +660.4%.
  • Income before tax amounts to 42.4% of revenue for ZLAB, versus a peer median of 215.3%.
ZLAB Competitors
Income Before Tax for ZLAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HCMHUTCHMED (China) LimitedLTM Jun 2025$535.03M USD+1525.1%—88.8%
ANLAdlai Nortye Ltd.LTM Jun 2024-$53.42M USD——823.1%
ZLABZai Lab LimitedLTM Jun 2026-$190.72M USD+10.3%—42.4%
AAPGAscentage Pharma Group InternationalFY2025-CN¥1.2B CNY-204.2%—215.3%
Peer median (excluding ZLAB) —+660.4%—215.3%

Competitors are the stored peer set for ZLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue144.31M215.04M266.72M398.99M460.16M
Cost of Revenue52.24M74.02M95.82M147.86M191.08M
Gross Profit92.07M141.02M170.9M251.13M269.08M
Gross Margin63.8%65.6%64.1%62.9%58.5%
Research & Development573.31M286.41M265.87M234.5M220.9M
Selling, General & Admin218.83M258.97M281.61M298.74M277.61M
Operating Expenses792.14M545.38M537.48M533.25M492.65M
Depreciation & Amortization6.49M8.23M9.03M11.86M15.01M
EBITDA(689.46M)(434.84M)(365.11M)(242.99M)(158.25M)
EBITDA Margin-477.8%-202.2%-136.9%-60.9%-34.4%
Operating Income(700.06M)(404.36M)(366.57M)(282.12M)(223.57M)
Operating Margin-485.1%-188.0%-137.4%-70.7%-48.6%
Interest Income2.19M14.58M39.8M37.11M33.05M
Interest Expense0002.25M5.21M
Other Income / Expenses(3.35M)(38.93M)31.95M25.01M45.11M
Income Before Tax(703.41M)(443.29M)(334.62M)(257.1M)(178.46M)
Pre-Tax Margin-487.4%-206.1%-125.5%-64.4%-38.8%
Income Tax Expense1.06M000(2.93M)
Net Income(704.47M)(443.29M)(334.62M)(257.1M)(175.54M)
Net Margin-488.2%-206.1%-125.5%-64.4%-38.1%
EPS (Basic)(75.80)(46.30)(34.60)(2.60)(1.60)
EPS (Diluted)(75.80)(46.30)(34.60)(2.60)(1.60)
Weighted Avg Shares9.3M9.58M9.66M98.95M109.53M
Weighted Avg Shares (Diluted)9.3M9.58M9.66M98.95M109.53M

Zai Lab Limited

NASDAQ:ZLAB

Intrinsic Alpha fair value

Locked

Current Price

$22.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.